The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab. Leveraging MD Anderson's clinical infrastructure and research expertise together with Summit's innovative, investigational, potential first-in-class PD-1/VEGF bispecific antibody, the collaboration is designed to quickly discover additional opportunities for ivonescimab, including several tumors outside of its current development plan.
MD Anderson will lead multiple clinical trials in several tumor types to evaluate the safety and potential clinical benefit of ivonescimab, including the possibility of identifying biomarkers through additional research activities. "We are excited to collaborate with MD Anderson to provide unique insights and expertise to further broaden the development of ivonescimab," said Allen S. Yang, M.
D., Ph.D.
, chief medical officer of Summit. "This collaboration will help accelerate the growing clinical development efforts for ivonescimab and help bring this innovative advancement on immunotherapy and anti-angiogenic standards to as many patients who may benefit as possible." Early work may include certain types of renal cell carcinoma, colorectal cancer, skin cancer, breast cancer and glioblastoma, which has the potential to rapidly expand the breadth and depth of the ivonescimab development program.
The bispecific antibody has shown significant pro.